Sector News

Fujifilm makes yet another deal to jack up cell and gene therapy capacity

March 27, 2022
Life sciences

In 2018, Japanese multinational conglomerate Fujifilm up and decided it wanted to become a major player in supplying cell and gene therapy manufacturing, so it purchased two key companies—one in the U.S. and in the other in Japan—to jump-start its goal.

Four years later, the spending spree continues: Fujifilm has gobbled up Shenandoah Biotechnology for an undisclosed sum, again to increase its cell and gene therapy capabilities.

The Warminster, Pennsylvania-based Shenandoah boosts Fujifilm’s ability to produce recombinant proteins—especially growth factors and cytokines—used in manufacturing cell and gene therapies.

Shenandoah also comes with an upgraded cGMP facility with bio-command software, a new Tuttnauer autoclave sterilizer, a 16×16 ColdBox, and new air handling and RODI water systems, according to its website.

“Shenandoah Biotechnology’s portfolio of recombinant proteins complement our advanced cell culture solutions and expertise in bioprocessing, providing our collective customers a single point of access for their life science research, discovery, and cell and gene therapy needs,” Yutaka Yamaguchi, CEO of Fujifilm Irvine Scientific, said in a release.

Fujifilm said it welcomed “all members” of the Shenandoah team. The privately held company was established in 2006.

In 2018, Fujifilm dove headfirst into the cell and gene therapy supply business with its simultaneous acquisition of Irvine Scientific Sales of California and IS Japan for $800 million.

Then, in September of last year, Fujifilm completed construction of a 250,000-square-foot facility in Tilburg, Netherlands. The site produces dry powder media and liquid media along with other raw materials used in producing cell and gene therapies. It also gave Fujifilm Irvine Scientific a hub from which to serve its customers in Europe.

By Kevin Dunleavy


comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).